Fabtech Technologies
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Fabtech Technologies' chief financial officer Kalpesh Chauhan resigned from the company, with his departure effective at the close of business on 12 November 2026 for personal and professional reasons. The resignation letter was dated 18 August 2026 and set the last working day as 12 November 2026, with a commitment to support handover of responsibilities during the notice period. A successor had not been named. Fabtech Technologies is a turnkey engineering, procurement and construction contractor for pharmaceutical, biotechnology and healthcare cleanroom and plant projects operating across more than 62 countries. Consolidated revenue was about ₹431 crore in the year to March 2026, with revenue of ₹167.07 crore in the first half of the current financial year.
Powered by Tijori
Fabtech Technologies' chief financial officer Kalpesh Chauhan resigned from the company, with his departure effective at the close of business on 12 November 2026 for personal and professional reasons. The resignation letter was dated 18 August 2026 and set the last working day as 12 November 2026, with a commitment to support handover of responsibilities during the notice period. A successor had not been named. Fabtech Technologies is a turnkey engineering, procurement and construction contractor for pharmaceutical, biotechnology and healthcare cleanroom and plant projects operating across more than 62 countries. Consolidated revenue was about ₹431 crore in the year to March 2026, with revenue of ₹167.07 crore in the first half of the current financial year.
Powered by Tijori
Fabtech Technologies secured a ₹21 crore turnkey design-and-build project in a CIS country for critical internal infrastructure of an advanced medical-device manufacturing facility. The scope covered integrated engineering and design, cleanroom systems, HVAC, building management and electrical systems, process and clean utilities, laboratory furniture and fire and life-safety systems with installation, testing and commissioning, while process equipment was to be sourced directly by the customer, and handover was targeted in about 12 months from availability of the civil front. The award followed a ₹24.6 crore UAE flavour-manufacturing turnkey order in August and the completion of a 14,000 sqm turnkey facility for Himalaya Wellness in Dubai in September. Orders awarded to the company have clustered between ₹30 crore and ₹120 crore, with first-quarter inflow of ₹96.5 crore including a ₹31.23 crore veterinary vaccine facility in Botswana. Consolidated revenue was ₹431.33 crore in the year to March, with more than 750 projects executed across 62 countries.
Powered by Tijori
Fabtech Technologies secured a ₹21 crore turnkey design-and-build project in a CIS country for critical internal infrastructure of an advanced medical-device manufacturing facility. The scope covered integrated engineering and design, cleanroom systems, HVAC, building management and electrical systems, process and clean utilities, laboratory furniture and fire and life-safety systems with installation, testing and commissioning, while process equipment was to be sourced directly by the customer, and handover was targeted in about 12 months from availability of the civil front. The award followed a ₹24.6 crore UAE flavour-manufacturing turnkey order in August and the completion of a 14,000 sqm turnkey facility for Himalaya Wellness in Dubai in September. Orders awarded to the company have clustered between ₹30 crore and ₹120 crore, with first-quarter inflow of ₹96.5 crore including a ₹31.23 crore veterinary vaccine facility in Botswana. Consolidated revenue was ₹431.33 crore in the year to March, with more than 750 projects executed across 62 countries.
Powered by Tijori
Fabtech Technologies secured an AED 9.92 million, or approximately ₹24.6 crore, turnkey project from Aroma King through its wholly owned UAE subsidiary, FTS Cleanrooms Systems LLC. The six-month project covered modular controlled environments, cold rooms, specialised flooring, HVAC systems and internal electrical works for a flavour manufacturing facility. The award expanded the UAE subsidiary’s work in controlled environments into food, flavour and ingredient manufacturing beyond life sciences. Fabtech reported consolidated revenue of ₹431.33 crore for FY26, while its order book stood at about ₹920 crore in the June 2026 quarter.
Powered by Tijori
Fabtech Technologies secured an AED 9.92 million, or approximately ₹24.6 crore, turnkey project from Aroma King through its wholly owned UAE subsidiary, FTS Cleanrooms Systems LLC. The six-month project covered modular controlled environments, cold rooms, specialised flooring, HVAC systems and internal electrical works for a flavour manufacturing facility. The award expanded the UAE subsidiary’s work in controlled environments into food, flavour and ingredient manufacturing beyond life sciences. Fabtech reported consolidated revenue of ₹431.33 crore for FY26, while its order book stood at about ₹920 crore in the June 2026 quarter.
Powered by Tijori
Aug 19 (Reuters) - Fabtech Technologies Ltd FABE.NS:
FABTECH TECHNOLOGIES - SUBSIDIARY SECURES AED 9.92 MILLION TURNKEY FLAVOUR PROJECT IN UAE
Source text: ID:nBSE6Wttph
Further company coverage: FABE.NS
(([email protected];))
Aug 19 (Reuters) - Fabtech Technologies Ltd FABE.NS:
FABTECH TECHNOLOGIES - SUBSIDIARY SECURES AED 9.92 MILLION TURNKEY FLAVOUR PROJECT IN UAE
Source text: ID:nBSE6Wttph
Further company coverage: FABE.NS
(([email protected];))
Fabtech Technologies' board on June 25, 2026 approved additional investments of up to ₹24 crore into its Sharjah-based wholly-owned subsidiary Fabtech Technologies LLC to strengthen EPC operations abroad. The board also cleared a ₹2.49 crore equity investment into FT Institutions Private Limited, a domestic pharma and healthcare focused subsidiary. The overseas subsidiary remains non-revenue generating, while FT Institutions reported revenue of ₹12.61 crore and a net profit of ₹0.38 crore for FY26. Both transactions are cash subscriptions at par and are expected to be completed within a year, subject to regulatory approvals. Separately, the board noted the completion of independent director Shyam Nagorao Khante’s tenure effective that day, and reconstituted its audit, nomination and remuneration, and CSR committees from June 26.
Powered by Tijori
Fabtech Technologies' board on June 25, 2026 approved additional investments of up to ₹24 crore into its Sharjah-based wholly-owned subsidiary Fabtech Technologies LLC to strengthen EPC operations abroad. The board also cleared a ₹2.49 crore equity investment into FT Institutions Private Limited, a domestic pharma and healthcare focused subsidiary. The overseas subsidiary remains non-revenue generating, while FT Institutions reported revenue of ₹12.61 crore and a net profit of ₹0.38 crore for FY26. Both transactions are cash subscriptions at par and are expected to be completed within a year, subject to regulatory approvals. Separately, the board noted the completion of independent director Shyam Nagorao Khante’s tenure effective that day, and reconstituted its audit, nomination and remuneration, and CSR committees from June 26.
Powered by Tijori
Fabtech Technologies has won a turnkey order worth roughly ₹31.23 crores from Botswana Vaccine Institute Limited to supply HVAC and Clean Room systems for a blending and filling project in Botswana. The contract covers design, supply, installation, testing, and commissioning, with a 14-month execution timeline. The international order bolsters Fabtech's order book and expands its footprint in the African market, complementing its existing Middle East and domestic operations.
Powered by Tijori
Fabtech Technologies has won a turnkey order worth roughly ₹31.23 crores from Botswana Vaccine Institute Limited to supply HVAC and Clean Room systems for a blending and filling project in Botswana. The contract covers design, supply, installation, testing, and commissioning, with a 14-month execution timeline. The international order bolsters Fabtech's order book and expands its footprint in the African market, complementing its existing Middle East and domestic operations.
Powered by Tijori
June 15 (Reuters) - Fabtech Technologies Ltd FABE.NS:
FABTECH TECHNOLOGIES - SECURES ORDER FROM BOTSWANA VACCINE INSTITUTE FOR 312.3 MILLION RUPEES
Source text: ID:nNSE3g1vym
Further company coverage: FABE.NS
(([email protected];))
June 15 (Reuters) - Fabtech Technologies Ltd FABE.NS:
FABTECH TECHNOLOGIES - SECURES ORDER FROM BOTSWANA VACCINE INSTITUTE FOR 312.3 MILLION RUPEES
Source text: ID:nNSE3g1vym
Further company coverage: FABE.NS
(([email protected];))
** Shares of Fabtech Technologies FABE.NS rise 12.6% to 182.8 rupees, their highest since Jan 19
** Pharma engineering firm's Q4 consol net profit rises about 46% Y/Y, aided by strong demand for its engineering services; rev up 17.5%
** Over 4.5 mln shares traded so far, about 7x 30-day avg
** Stock down 10.8% YTD
(Reporting by Aleef Jahan in Bengaluru)
** Shares of Fabtech Technologies FABE.NS rise 12.6% to 182.8 rupees, their highest since Jan 19
** Pharma engineering firm's Q4 consol net profit rises about 46% Y/Y, aided by strong demand for its engineering services; rev up 17.5%
** Over 4.5 mln shares traded so far, about 7x 30-day avg
** Stock down 10.8% YTD
(Reporting by Aleef Jahan in Bengaluru)
** Shares of Fabtech Technologies FABE.NS slip 8.4% to 149.50 rupees
** The medical equipment and supply company posts third-quarter consol net loss of 56.8 million rupees ($627,393) vs a profit of 204.6 million rupees in the year-ago period
** Third-quarter revenue down 39.8% Y/Y
** Trading vols over 2x the 30-day average at 1.1 million shares
** FABE stock down ~24% so far in 2026
($1 = 90.3740 Indian rupees)
(Reporting by Vijay Malkar)
(([email protected];))
** Shares of Fabtech Technologies FABE.NS slip 8.4% to 149.50 rupees
** The medical equipment and supply company posts third-quarter consol net loss of 56.8 million rupees ($627,393) vs a profit of 204.6 million rupees in the year-ago period
** Third-quarter revenue down 39.8% Y/Y
** Trading vols over 2x the 30-day average at 1.1 million shares
** FABE stock down ~24% so far in 2026
($1 = 90.3740 Indian rupees)
(Reporting by Vijay Malkar)
(([email protected];))
** Shares of Fabtech Technologies FABE.NS drop to exchange-allowed maximum of 182.40 rupees in trading debut
** FABE valued at 8.11 bln rupees ($91.4 mln) as of 12:01 IST
** Stock opened at 192 rupees, 0.5% higher than IPO price of 191 rupees
** FABE provides turnkey engineering solutions for pharmaceuticals, biotech and healthcare companies
** Co's 2.3 bln rupee IPO, which was entirely an issue of new shares, was subscribed 2.03x
** Trading vols 4 mln shares so far
** Proceeds from IPO to be used for funding working capital requirements, pursuing inorganic growth through acquisitions, and other corporate purposes
($1 = 88.7170 Indian rupees)
(Reporting by Vijay Malkar)
(([email protected];))
** Shares of Fabtech Technologies FABE.NS drop to exchange-allowed maximum of 182.40 rupees in trading debut
** FABE valued at 8.11 bln rupees ($91.4 mln) as of 12:01 IST
** Stock opened at 192 rupees, 0.5% higher than IPO price of 191 rupees
** FABE provides turnkey engineering solutions for pharmaceuticals, biotech and healthcare companies
** Co's 2.3 bln rupee IPO, which was entirely an issue of new shares, was subscribed 2.03x
** Trading vols 4 mln shares so far
** Proceeds from IPO to be used for funding working capital requirements, pursuing inorganic growth through acquisitions, and other corporate purposes
($1 = 88.7170 Indian rupees)
(Reporting by Vijay Malkar)
(([email protected];))
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Fabtech Technologies do?
Fabtech Technologies is a key turnkey engineering solution provider in pharmaceuticals capex space, offering comprehensive start to finish solutions encompassing designing, engineering, procurement, installation and testing of pharmaceutical equipment for a wide range of customers. It offers services in greenfield projects for a wide range of customers primarily in the pharmaceutical, healthcare and biotech sector across various geographies, particularly key emerging economies.
Who are the competitors of Fabtech Technologies?
Fabtech Technologies major competitors are . Market Cap of Fabtech Technologies is ₹606 Crs. While the median market cap of its peers are ₹0 Crs.
Is Fabtech Technologies financially stable compared to its competitors?
Fabtech Technologies seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Fabtech Technologies pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Fabtech Technologies latest dividend payout ratio is 6.95% and 3yr average dividend payout ratio is 8.71%
How has Fabtech Technologies allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments, Accounts Receivable
How strong is Fabtech Technologies balance sheet?
Balance sheet of Fabtech Technologies is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Fabtech Technologies improving?
No, profit is decreasing. The profit of Fabtech Technologies is ₹35.56 Crs for TTM, ₹38.36 Crs for Mar 2026 and ₹46.45 Crs for Mar 2025.
Is the debt of Fabtech Technologies increasing or decreasing?
Yes, The net debt of Fabtech Technologies is increasing. Latest net debt of Fabtech Technologies is -₹177.08 Crs as of Sep-26. This is greater than Mar-26 when it was -₹374.35 Crs.
Is Fabtech Technologies stock expensive?
Fabtech Technologies is not expensive. Latest PE of Fabtech Technologies is 17.02, while 3 year average PE is 17.13. Also latest EV/EBITDA of Fabtech Technologies is 17.08 while 3yr average is 21.53.
Has the share price of Fabtech Technologies grown faster than its competition?
Fabtech Technologies has given lower returns compared to its competitors. Fabtech Technologies has grown at ~-42.22% over the last 1yrs while peers have grown at a median rate of 0%
Is the promoter bullish about Fabtech Technologies?
Promoters seem to be bullish about the company. Latest quarter promoter holding is 69.03% and last quarter promoter holding is 68.94%.
Are mutual funds buying/selling Fabtech Technologies?
There is Insufficient data to gauge this.